(RTTNews) -  Tuesday, Masimo Corp. (MASI: News ), the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced the Food and Drug Administration or FDA clearance of its latest innovation, Masimo Rainbow SET Acoustic Monitoring providing noninvasive and continuous respiration rate or RRa that is accurate, easy-to-use, and enhances patient compliance.

Masimo Rainbow SET Acoustic Monitoring may enable earlier detection of respiratory compromise and patient distress, offering a breakthrough in patient safety for post-surgical patients on the general floor, the company said.
Masimo Founder and Chief Executive Officer, Joe Kiani, said, "Solving 'unsolvable' problems that have plagued patient monitoring is key to advancing medicine and improving patient care. Masimo Rainbow SET Acoustic Monitoring addresses a longstanding and growing need to accurately and easily monitor patient breathing, which is expected to improve patient safety and decrease the cost of care in hospitals. It also adds another compelling reason for hospitals to choose the Masimo Rainbow SET upgradeable platform for pulse oximetry, Pulse CO-Oximetry, and now -- Acoustic Monitoring."

Click here to receive FREE breaking news email alerts for Masimo Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com